Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer

Michal Sarfaty, Peter S. Hall, Kelvin K.W. Chan, Kiran Virik, Moshe Leshno, Noa Gordon, Assaf Moore, Victoria Neiman, Eli Rosenbaum, Daniel A. Goldstein

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences